Telomir Publishes Telomir-Zn AMD Preclinical Findings
MIAMI, Fla. — September 17, 2026 Telomir Pharmaceuticals announced the peer-reviewed publication of new preclinical research showing that Telomir-Zn...
TNBC
Advertisement
Telomir Advances Telomir-Zn in Human and Canine Osteosarcoma
MIAMI, Fla. — September 14, 2026 Telomir Pharmaceuticals, Inc. announced new research conducted with The Ohio State University College...
Context Therapeutics Doses First Patient in CT-202 Phase 1
PHILADELPHIA — September 9, 2026 Context Therapeutics Inc. announced that the first patient has been dosed in the Phase...
Daiichi Sankyo and AstraZeneca Receive EU Approval for Datroway in First-Line Metastatic TNBC
TOKYO, July 31, 2026 Daiichi Sankyo and AstraZeneca announced that the European Commission (EC) has approved Datroway® (datopotamab deruxtecan)...
Intensity Therapeutics Restarts Phase 2 TNBC Trial
SHELTON, Conn., July 15, 2026 Intensity Therapeutics, Inc. has restarted patient treatment in its Phase 2 INVINCIBLE-4 clinical trial...
Advertisements
AstraZeneca, Daiichi Sankyo Advance Datroway Toward EU Approval
CAMBRIDGE, UK & TOKYO, Japan, June 26, 2026 AstraZeneca and Daiichi Sankyo have moved one step closer to expanding...
Gilead’s Trodelvy Wins CHMP Support in 1L TNBC
FOSTER CITY, Calif., May 25, 2026 Gilead Sciences announced that the European Medicines Agency’s Committee for Medicinal Products for...
Datroway by AstraZeneca Approved as First TROP2 ADC for TNBC
Cambridge, United Kingdom – May 22, 2026 AstraZeneca and Daiichi Sankyo announced that the U.S. Food and Drug Administration...
Tigerlily Foundation and BMS Expand Clinical Trial Access
Washington, D.C. – May 15, 2026 Tigerlily Foundation announced a new collaboration with Bristol Myers Squibb focused on improving...
Mabwell 9MW2821 Advances to Phase III in TNBC Trial
SHANGHAI, April 23, 2026 Mabwell has announced the initiation of a Phase III clinical trial for its proprietary Nectin-4-targeting...
Advertisement
